Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Prostate-specific membrane antigen (PSMA) is a key target for prostate carcinoma treatment.
• Current immunotherapies for PSMA have limitations like high costs and short antibody half-life.

Purpose of the Study:

• To develop and evaluate a novel DNA-encoded monoclonal antibody (DMAb) strategy for prostate cancer immunotherapy.
• To assess the efficacy of anti-PSMA DMAb in controlling tumor growth and prolonging survival in a preclinical mouse model.

Main Methods:

• Synthetic DNA plasmids encoding a human anti-PSMA mAb were constructed.
• Electroporation-enhanced intramuscular injection of DMAb plasmids was administered to mice.
• In vivo production of anti-PSMA antibody and its therapeutic effects were analyzed.

Main Results:

• DMAb plasmid injection led to functional and durable anti-PSMA antibody production in vivo.
• The produced anti-PSMA antibody effectively controlled tumor growth and prolonged survival in mice.
• Therapeutic effects were likely mediated by antibody-dependent cellular cytotoxicity (ADCC) involving NK cells.

Conclusions:

• DNA-encoded monoclonal antibody (DMAb) therapy is a promising novel strategy for prostate cancer immunotherapy.
• This approach overcomes limitations of conventional monoclonal antibody therapy.
• Further investigation into DMAb therapy for human prostate cancer and other malignancies is warranted.